Amphastar Pharmaceuticals (AMPH)
(Real Time Quote from BATS)
$47.88 USD
-0.73 (-1.50%)
Updated Sep 24, 2024 01:38 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AMPH 47.88 -0.73(-1.50%)
Will AMPH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AMPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMPH
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics
Amphastar Pharmaceuticals (AMPH) Tops Q2 Earnings and Revenue Estimates
AMPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
HCA Healthcare (HCA) Beats on Q2 Earnings, Ups 2024 EPS View
UnitedHealth Group (UNH) Q2 Earnings Beat on Strong Optum Unit
Why Amphastar (AMPH) is Poised to Beat Earnings Estimates Again
Other News for AMPH
Amphastar Pharmaceuticals Inc (AMPH) Trading 2.97% Higher on Sep 13
Bullish Two Hundred Day Moving Average Cross - AMPH
Amphastar Pharmaceuticals Offers Interesting Growth And Income Prospects
Amphastar: Perplexing Pipeline, Lumpy Revenues - I'm On Sidelines
Insider Sale: Director Floyd Petersen Sells Shares of Amphastar Pharmaceuticals Inc (AMPH)